2-Octynoic Acid Inhibits Hepatitis C Virus Infection through Activation of AMP-Activated Protein Kinase

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yang, Darong ^a   Xue, Binbin ^a   Wang, Xiaohong ^a   Yu, Xiaoyan ^a   Liu, Nianli ^a   Gao, Yimin ^a   Liu, Chen ^b   Zhu, Haizhen ^a  

^a HUNAN UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OCTYNOIC ACID; ACETYL COENZYME A CARBOXYLASE; ANTIVIRUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA 122; UNCLASSIFIED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; GENE; GENETIC TRANSFECTION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INNATE IMMUNITY; INTERFERON STIMULATED GENE; LIPID STORAGE; LIVER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REPLICON; RNA INTERFERENCE; RNA REPLICATION; VIRUS GENOME; VIRUS INHIBITION; VIRUS PARTICLE; VIRUS REPLICATION; WESTERN BLOTTING;

AMP-ACTIVATED PROTEIN KINASES; ANTIVIRAL AGENTS; CELL LINE; ENZYME ACTIVATION; FATTY ACIDS, MONOUNSATURATED; GENE EXPRESSION REGULATION; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERON REGULATORY FACTORS; LIPID METABOLISM; MICRORNAS; VIRUS REPLICATION;

HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 84878607908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064932     Document Type: Article

References (29)

1. Laucer GM, Walker BD, (2001) Hepatitis C virus infection. N Engl J Med 345: 41-52.
2. Hoofnagle JH, Seeff LB, (2006) Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 355: 2444-2451.
3. Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J, (2011) Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant virus. Gastroenterology 141: 1067-1079.
4. Shindo H, Maekawa S, Komase K, Sueki R, Miura M, et al. (2012) Characterization of naturally occurring protease inhibitor-resistance mutations in genotype 1b hepatitis C virus patients. Hepatol Int 6: 482-490.
5. Halfon P, Locarnini S, (2011) Hepatitis C virus resistance to protease inhibitors. J Hepatol 55: 192-206.
6. Moradpour D, Penin F, Rice CM, (2007) Replication of hepatitis C virus. Nat Rev Micro 5: 453-463.
7. Herker E, Harris C, Hernandez C, Carpentier A, Kaehlcke K, et al. (2010) Efficient hepatitis C virus particle formation requires diacyglycerol acyltranferase-1. Nat Med 16: 1295-1298.
8. Chin G, Yeston J, (2010) Lipids go viral. Science 330: 297.
9. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, et al. (2007) The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol 9: 1089-1097.
10. Ikeda M, Abe K, Yamada M, Dansako H, Naka K, et al. (2006) Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44: 117-125.
11. Wang CF, Gale M, Keller BC, Huang H, Brown MS, et al. (2005) Identification of FBL2 as a geranylgeranylated required for hepatitis C cellular protein virus RNA replication. Mol Cell 18: 425-434.
12. Amano K, Leung PC, Rieger R, Quan C, Wang X, et al. (2005) Chemical Xenobiotics and Mitochondrial Autoantigens in Primary Biliary Cirrhosis: Identification of Antibodies against a Common Environmental, Cosmetic, and Food Additive, 2-Octynoic Acid. J Immunol 174: 5874-5883.
13. Kim J, Matsuyama S, Suzuki T, (2005) 4, 8-Dimethyldecanal, the aggregation pheromone of Tribolium castaneum, is biosynthesized through fatty acid pathway. J Chem Ecol 31: 1381-1400.
14. Guo JT, Bichko VV, Seeger C, (2003) Effect of alpha interferon on the hepatitis C virus replication. J Virol 75: 8516-8523.
15. Blight KJ, McKeating JA, Marcotrigiano J, Rice CM, (2002) High permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76: 13001-13014.
16. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, et al. (2007) Hepatitis C virus triggers cell death through innate intracellular antiviral defense system. Gastroenterology 133: 1649-1659.
17. Yang D, Liu N, Zuo C, Lei S, Wu X, et al. (2011) Innate immune response of primary human hepatocytes with hepatitis C viral infection. PLoS One 6: e27552.
18. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, et al. (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA 102: 9294-9299.
19. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, et al. (2005) Complete replication of hepatitis C virus in cell culture. Science 309: 623-626.
20. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, et al. (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11: 791-796.
21. Mankouri J, Tedbury PR, Gretton S, Hughes ME, Griffin SD, et al. (2010) Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase. Proc Natl Acad Sci USA 107: 11549-11554.
22. Zhu H, Zhao H, Collins CD, Eckerrode SE, Ruan Q, et al. (2003) Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 37: 1180-1188.
23. Zhu H, Liu C, (2003) Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virol 77: 5493-5498.
24. Rice CM, (2011) New insights into HCV replication: potential antiviral targets. Top Antivir Med 19: 117-120.
25. Tatgett-Adams P, Graham EJ, Middleton J, Palmer A, Shaw SM, et al. (2011) Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action. J Virol 85: 6353-6368.
26. De Francesco R, Migliaccio G, (2005) Challenges and successes in developing new therapies for hepatitis C. Nature. 436: 953-960.
27. Elmén J, Lindow M, Schutz S, Lawrance M, PetriA, et al, (2008) LNA-mediated microRNA silencing in nonhuman primates. Nature 452: 896-899.
28. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198-201.
29. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, et al. (2008) Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4 serum HCV RNA level and liver fibrosis. Gastroenterology 134: 416-423.